Previous 10 | Next 10 |
2023-11-10 10:31:32 ET More on Inhibrx Seeking Alpha's Quant Rating on Inhibrx Historical earnings data for Inhibrx For further details see: Inhibrx posts Q3 results
Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO , Nov. 9, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical ...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
Inhibrx Inc. (INBX) is expected to report $-1.01 for Q3 2023
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma PR Newswire SAN DIEGO , Nov. 2, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of...
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada PR Newswire SAN DIEGO , Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicat...
2023-08-29 09:15:36 ET Clinical-stage biopharmaceutical company Inhibrx ( NASDAQ: INBX ) entered into a securities purchase agreement for a private placement financing that is expected to result in gross proceeds of ~$200M. In the PIPE, Inhibrx ( INBX ) is selling an agg...
Inhibrx Announces $200 Million Private Placement Financing PR Newswire SAN DIEGO , Aug. 29, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for...
2023-08-17 16:41:26 ET Summary INBX is researching a breakthrough for Alpha-1 Antitrypsin deficiency and has received regulatory support for its INBRX-101 pipeline. The AATD treatment market is expected to experience robust growth in the coming years. INBRX-101 has received Fa...
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical...
News, Short Squeeze, Breakout and More Instantly...
Inhibrx Inc. Company Name:
INBX Stock Symbol:
NASDAQ Market:
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...
Inhibrx Biosciences Inc. (INBX) is expected to report for Q1 2024